treated with sulfaquinoxaline to decrease the incidence of coccidial infections. The animals were housed in a room maintained at a temperature of 23 ± 3 °C and a relative humidity of 50 ± 10% with artificial lighting from 0800 to 2000 and with 13-18 air changes per hour.
The rabbits were randomly divided into three equal groups including 7 rabbits in each. In the first group, normal (5 mg/kg) and toxic doses (50 mg/kg) of enrofloxacin (10 times the normal dose) were given (group 1). In the second group, the normal dose (5 mg/kg) of enrofloxacin was given for 6 weeks (group 2). The last group received no drug and was designated as a negative group (group 3).
In the first group, enrofloxacin was injected intravenously via the auricular vein at the dose of 5.0 mg/ kg bw (Enrofloxacin HCl, Baytril, 10%, Bayer, Turkey) over 10 min. The animals were assessed by ECG, haematology, and serum biochemical analysis at 5, 10, 15, 20, and 30 min after the end of the first infusion. Then infusion continued to peracute toxic effect, enrofloxacin at a 10-fold dose of 50 mg/kg was injected over 10 min, and each parameter was re-evaluated at 5, 10, 15, 20, 30, 45 , and 60 min after the end of the infusion to the same animals. Serum enrofloxacin concentration and its metabolite ciprofloxacin were measured by using a standard highperformance liquid chromatographic method. In the second group, for chronic toxic effect, the normal dose (5 mg/kg) of enrofloxacin was given for 6 weeks. ECG of all the conscious animals was recorded every week. Serum LDH, AST, CK, and CK-MB isoenzyme activities, and cTnI levels and TAC and TOS were determined in all animals at the sampling time. A clinical examination was performed, body weights were measured weekly, and food and water consumption recorded in the second group. For all groups, at the end of experiment, necropsy was performed and gross findings and histology were evaluated. 2.4. Assessment of ECG recordings in the conscious rabbit ECG records were taken by direct writing electrocardiograph (Nihon Kohden, Cardiofax Vet, Japan). ECG was standardised at 1 mV = 20 mm, with a chart speed of 50 mm/s with the filter off. Lead II was used for the measurements of intervals/durations and amplitudes. Leads I, III, aVR, aVL, and aVF were also checked for any abnormalities. Corrected QT values (QTc) were calculated by using Carlsson's formula (Carlsson et al., 1993) [QTc = QT-0.175(RR -300)].
Biochemical and haematological measurement
The activities of LDH, AST, CK, and CK-MB isoenzyme, and cTnI levels were assayed colorimetrically, according to the standard procedures using commercially available diagnostic kits (DiaSys Diagnostic Systems, Holzheim, Germany). Furthermore, haematological parameters were determined using an automatic analyser (Abacus Junior Vet Systems, Budapest, Hungary).
Serum total antioxidant capacities, total oxidant status, and oxidative stress index
Total antioxidant capacities and total oxidant status capacities were determined colorimetrically (PowerWave XS, BioTek Instrument, Bedfordshire, UK) using a commercial kit (Rel Assay Diagnostic, Gaziantep, Turkey) as previously described by Durgut et al. (2013) . Serum TAC was determined using a novel automated measurement method developed elsewhere (Erel, 2004) . The results are expressed as µmol of Trolox equivalent/litre.
Total oxidant status levels were measured using commercially available kits (Rel Assay Diagnostic, Gaziantep, Turkey). The assay was calibrated with hydrogen peroxide (H 2 O 2 ), and the results were expressed in terms of micromolar H 2 O 2 equivalent per litre (µmol H 2 O 2 equivalent/L) (Erel, 2005) . The OSI was calculated as the ratio of TOS to TAC to determine the extent of oxidative stress (Erel, 2004 (Erel, , 2005 . OSI values were calculated using the following formula: OSI = [(TOS, μmol/L)/(TAC, mmol Trolox equivalent/L) × 100] (Erel, 2005) .
Measurement of serum drug concentration
A volume of 3 mL of blood was drawn from the auricular vein to measure the serum drug concentration. The blood samples were centrifuged at 1500 × g for 30 min at 4 °C. The serum was stored at -80 °C until the drug concentration was measured. Determinations of the enrofloxacin concentration were performed using a standard highperformance liquid chromatographic method (Model LC-6A with UV spectrophotometric detector model SPD-6A, data processor model chromatopac CR-6A; Shimadzu Corp, Analytical Instrument Plant, Kyoto, Japan), as described by Devreese et al. (2014) . Enrofloxacin was extracted from plasma using dichloromethane and analysed by reverse-phase chromatography. The mobile phase was a mixture of buffer (pH 2.2) and acetonitrile (80:20, v/v) . Heptane sulfonic acid-Na (1.1 g/L) added as the ion-pairing reagent. Ultraviolet absorbance measured at 278 nm was used for detection, with the flow rate maintained at 2 mL/min. The linearity of the method was examined by linear regression analysis of calibration curves in plasma from goats. The recovery of enrofloxacin was >90%. The limit of quantification of enrofloxacin was 0.01 pg/mL.
Necropsy and histopathology
At scheduled termination, all rabbits were sacrificed by exsanguination from the neck. Complete gross postmortem examinations were performed on all terminated animals. The heart was obtained from all rabbits. The tissues were fixed with 10% neutral buffered formalin solution. The tissues were routinely processed, embedded in paraffin, and sectioned at 3-5 µm. The sections were stained with haematoxylin-eosin stain for microscopic examination. All organs and tissues taken from all animals in the control and highest dose groups were examined microscopically. All gross lesions as defined by the study histologist were also included in the examination.
Statistical analysis
The groups and different time changes were evaluated by one-way analysis of variance (ANOVA) with repeated measurement design. Two-way ANOVA with repeated measurement between groups was done with Duncan's multiple comparison test, and Bonferroni's multiple comparison test was used for differences between weeks. The results were presented as means ± SEM. A P value <0.05 was regarded as statistically significant.
Results

Peracute enrofloxacin administration
Two discrete results emerged from the study. First, no evidence of weakness and no adverse effects on general health were observed in rabbits treated at the recommended dosage regimes or in a 10 times higher dose of 50 mg/kg of enrofloxacin in all groups. Second, there was no significant difference in the QT interval and QTc, and other ECG parameters with the normal dose of 5 mg/kg, and the highest dose of 50 mg/kg in rabbits during the experiment. The electrophysiological effects of enrofloxacin are summarised in Tables 1A and 1B. A number of issues were identified. No statistically significant changes in heart rate were observed at any of the dose levels in group 1 during the experimental procedure, but there was a dose-related increase in plasma concentrations of enrofloxacin. The results of this investigation show that enrofloxacin at clinically relevant dose of 5 mg/kg and in a 10 times higher dose of 50 mg/ kg should have no torsadogenic potential. One of the more significant findings to emerge from this study is that enrofloxacin in the conscious rabbits had no effect on QTc and causes QT prolongation only when administered at normal and higher doses injected intravenously (Tables  1A and 1B) .
As shown in Table 2 , MCHC count significantly increased in group 1 when compared with that at 0, 30, and 60 min, and MCV count was significantly decreased at 30 min and increased at 60 min. As shown in Table 3 , CK significantly was increased at 60 min compared with that at 0 and 30 min.
No statistically significant changes in serum biochemical findings (as can be seen in Table 3 ), or TAC, TOS, or OSI were observed in group 1 ( Table 4 ). As Table  5 shows, there was a significant difference (P < 0.05) in the serum concentration of enrofloxacin and its metabolite ciprofloxacin between the sampling times.
Subacute enrofloxacin administration
As shown in Table 6 , the body weight gain (g) of rabbits did not significantly change in group 2 during the experimental period. Food consumption by the rabbits in group 2 did not change, and water consumption decreased during the experimental period (data not shown).
The experimental design showed that enrofloxacin or its metabolite ciprofloxacin, when administered at the recommended dose of 5 mg/kg once daily for 6 weeks in group 2, did not cause a significant prolongation in the QT interval (Tables 7 and 8 ). It appears that enrofloxacin, at clinically relevant doses and in a 10 times higher dose of 50 mg/kg, had no torsadogenic potential either. No statistically significant changes were observed in haematological findings or serum biochemistry, TAC, TOS, or OSI during the experimental period in group 2 (as can be seen in Tables 9-11) . No statistically significant changes were observed in mean serum concentration of enrofloxacin or its metabolite ciprofloxacin between the sampling times either (Table 12) . There was no statistical significance in the same column (P > 0.05). Values are presented as mean ± SEM. There was no statistical significance in the same column (P > 0.05). Values are presented as means ± SEM. No histopathological changes were observed in the treatment groups except for some minor abnormalities including hyperaemia in some heart areas when compared to the negative control group (Figure 1A-1C) .
Discussion
Fluoroquinolones are widely used and well tolerated antibacterial agents for veterinary medicine. In our review of the literature, no data were found on the association between enrofloxacin and QT prolongation and TdP in There was no statistical significance in the same line (P > 0.05). Values are presented as means ±SEM. There was no statistical significance in the same line (P > 0.05). Values are presented as means ± SEM.
clinically healthy rabbits. Therefore, the aim of this study was to assess the importance of enrofloxacin using the in vivo clinically healthy rabbit model with the normal dose and in a 10 times higher dose injection with various electrocardiographic parameters including RR, PQ, and QT intervals; QRS duration; QT/QTc prolongation; or TdP. Some authors speculated that increases in heart rate (HR), with accompanying decreases in QT intervals, could be masking an inherent increase in QT interval, identified with numerous drugs (Haverkamp et al., 2000; De Ponti et al., 2001; Redfern et al., 2003; Kijtawornrat et al., 2006; Ozkanlar et al., 2014) . The reason for this was that a correction formula that adequately corrected QT intervals was used in the current study. Drug-induced QT prolongation is relatively common in clinical practice (De Ponti et al., 2001; Redfern et al., 2003; Ozkanlar et al., 2005b) . It has been reported that sparfloxacin and grepafloxacin can prolong the QT interval to cause lethal ventricular arrhythmias (Bertino and Fish, 2000; Frothingham, 2001; Owens, 2001) . Therefore, this finding has important implications for developing a therapeutic strategy. To date, there has been no scientific research on enrofloxacin associated effects on the rabbit's heart. Rabbits may be dosed with 2.5-5 mg/ kg bw per day for 3-5 days by oral administration or by intramuscular injection (Elmas et al., 2006) . In the present study, the normal dose of 5 mg/kg and the higher dose of 50 mg/kg were used in rabbits peracutely to investigate the relationship between serum concentration (the normaldose and the higher-dose injection of enrofloxacin). In the current experimental period of peracute (group 1) and subacute application (Group 2), no QT prolongation, recurrent syncope, or sudden cardiac death secondary to atypical polymorphic ventricular tachycardia were Enrofloxacin (mg/L) 0 ± 0 0 ± 0 0 ± 0 1.52 ± 0.14 0 ± 0 0.98 ± 0. observed. In the current study, no evidence of abnormal ECG parameters was detected including RR, PQ, and QT intervals; QRS duration and QTc; and heart rate at normal and even a 10 times higher dose. A possible explanation for these results may be that heart tissue of the rabbit may be affected by even higher doses than those used in this study. TdP is very important in terms of developing effective preclinical testing strategies and interpreting the data accurately (Frothingham, 2001; Redfern et al., 2003) . Nevertheless, there was a significant difference (P < 0.05) in the serum concentration of enrofloxacin and its metabolite ciprofloxacin (a major metabolite of enrofloxacin) at sampling intervals (as can be seen in Tables 5 and 12 ). In contrast to earlier findings, however, no evidence of QT/QTc prolongation or potentially fatal ventricular arrhythmias associated with quinolones (Bertino and Fish, 2000; Frothingham, 2001; Owens, 2001) was detected in the current study. Hence, the data presented here demonstrate that enrofloxacin had no torsadogenic potential in rabbits at 5 mg/kg or higher dose of 50 mg/ kg. It is possible, therefore, that this would create a more clinically relevant situation.
The plasma AST, LDH, and CK enzyme activities are important measures of both early and late phases of cardiac injury especially during clinical follow up (Saad et al., 2001) . In the present study, the activities of all these three enzymes in plasma did not increase. They are not specific for myocardial injury individually; however, evaluation of these enzymes together may be an indicator of myocardial injury. Serum cTnI and CK are the preferred markers for the detection of minor ischemic cardiac injury (Apple et al., 1997) . By treating the rabbits with enrofloxacin, AST, LDH, and CK enzyme activities and cTnI did not significantly change. This suggests that enrofloxacin may not have adverse effect on enzyme activities. Oxidative stress is generally described as an imbalance between oxidant and antioxidant levels (Lykkesfeldt and Svendsen, 2007) . Nitric oxide (NO), essential for the proper functioning of the cardiovascular system, is derived from L-arginine by NO synthase (NOS) in endothelial cells. NO synthase inhibition produces various cardiovascular abnormalities and ventricular contractile dysfunction (Loscalzo and Welch, 1995; Dickinson and Forman, 2002) . Although no previous report has investigated TAS, TOS, and OSI as biomarkers of oxidative stress and antioxidant defence related to treating the rabbits with enrofloxacin, a possible explanation for this might be that free oxidant radicals are not produced.
The histopathology of the heart in the treatment groups did not show any remarkable changes, which was similar to the negative control when stained with haematoxylin and eosin and assessed using light microscopy. It can thus be suggested that peracute and subacute enrofloxacin application may have not adverse effects on myocardial tissue.
The first major finding is that enrofloxacin, at clinically relevant dose of 5 mg/kg and even excessive dosing (10 times higher dose of 50 mg/kg), has no electrophysiological abnormalities particularly QT prolongation or torsadogenic effect. It was also shown that administration of a daily single dose of enrofloxacin intravenously was a safe application protocol. This finding might be of use for safe administration of enrofloxacin to animals and especially to rabbits during infectious disease. However, more clinical studies are needed to identify possible combinations of medications that have a potential for a proarrhythmic effect.
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